IBI 319
Alternative Names: Bispecific monoclonal antibodies - Innovent Biologics/Eli Lilly and Company; IBI-319Latest Information Update: 28 May 2024
At a glance
- Originator Innovent Biologics
- Developer Eli Lilly and Company; Innovent Biologics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Cancer(Late-stage disease, Second-line therapy or greater) in China (IV, Infusion)
- 03 Jun 2022 Efficacy, pharmacokinetics and adverse events data from a phase I trial in Cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 07 Nov 2021 NMPA approves IND application for IBI 319 in cancer in China prior to April 2021